Antimicrobial resistance and virulence patterns of Helicobacter pylori among patients with suspected peptic ulcer disease in disenfranchised settings

在弱势群体环境中,疑似消化性溃疡患者中幽门螺杆菌的抗菌素耐药性和毒力模式

阅读:1

Abstract

BACKGROUND: The epidemiology of Helicobacter pylori in Lebanon is underreported. We aimed to estimate the infection proportion, clarithromycin resistance, and virulence determinants of H. pylori among symptomatic patients with suspected peptic ulcers in Tripoli, North Lebanon. METHODS: Eighty-seven patients undergoing routine endoscopy screening for peptic ulcers were selected. Culture and Allplex™ H. pylori and ClariR Assay were performed. Antimicrobial susceptibility testing for clarithromycin, tetracycline, levofloxacin, and rifampicin was performed using the E-test method. The virulence factors (cagA, vacA, dupA, iceA1, iceA2, and oipA) were screened and/or typed by PCR. RESULTS: Overall, 32.2 % (28/87) of the patients were found to be infected with H. pylori. Five isolates were resistant to clarithromycin, associated with specific point mutations of A2143G (4/5) or A2142C (1/5). The vacA was found in all tested isolates, with s2m2 being the predominant vacA genotype. The 3' end variable region of cagA was identified in 44.4% of isolates, where cagA typing indicated their belonging to Western types. The other virulence determinants were dupA (77.8%), iceA1 (61.1%), oipA (55.6%), and iceA2 (50%). CONCLUSIONS: Our findings demonstrate the circulation of H. pylori among symptomatic patients with suspected peptic ulcers in Lebanon, characterized by a rich and diverse pool of virulence genes and the emergence of resistance to clarithromycin and levofloxacin. Large-scale surveillance is crucial for quantifying the burden of H. pylori infection, monitoring antimicrobial resistance trends, and ensuring timely updates to eradication treatment policies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。